The estimated Net Worth of Mary Di Biase is at least $295 Thousand dollars as of 9 September 2024. Dr Biase owns over 2,642 units of X4 Pharmaceuticals stock worth over $199,486 and over the last 3 years he sold XFOR stock worth over $95,510.
Dr has made over 15 trades of the X4 Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,642 units of XFOR stock worth $1,744 on 9 September 2024.
The largest trade he's ever made was selling 67,695 units of X4 Pharmaceuticals stock on 1 November 2023 worth over $49,417. On average, Dr trades about 6,717 units every 47 days since 2021. As of 9 September 2024 he still owns at least 289,110 units of X4 Pharmaceuticals stock.
You can see the complete history of Dr Biase stock trades at the bottom of the page.
Dr. Mary DiBiase Ph.D. is the Chief Operating Officer at X4 Pharmaceuticals.
Mary's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON, MA, 02134.
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa, and Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals executives and other stock owners filed with the SEC include: